clinical trial · NCT07646353
First-in-Human Dose-escalation of GSK4425689A: Safety, Tolerability, and PK in Healthy Adults
Malaria, FalciparumGSK4425689A SCGSK4425689A IVPlacebo
brief summary
This study will assess the safety, tolerability, and pharmacokinetic properties of GSK4425689A monoclonal antibody (mAb) in healthy adults, when administered by either intravenous (IV) or subcutaneous (SC) routes.
started
Jul 27, 2026
primary completion
Apr 10, 2028
completion
Apr 10, 2028
last updated
Oct 5, 2026
official title
A First-in-Human Dose-escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GSK4425689A in Healthy Adult Participants
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol